Clinical Trial

MTS109 in Patients With Refractory Autoimmune Diseases

Name: MTS109 in Patients With Refractory Autoimmune Diseases — clinical trial record (NCT07526350)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is the first-in-human trial of MTS109 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS109 in moderate to severe autoimmune diseases.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2026-04-06; most recent amendment 2026-06-26.

Trial Details

NCT Number	NCT07526350
Lead Sponsor	Shanghai Changzheng Hospital Collaborators: Metis Techbio
Conditions	Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis (SSc), ANCA-Associated Vasculitis (AAV), Sjogren's Syndrome (SS)
Enrollment	15 participants
Start Date	2026-03-24
Primary Completion	2028-04-01 (estimated)
Study Completion	2029-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-30